New research to be presented at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting found no significant differences between omalizumab (Xolair) and multi-food oral immunotherapy (mOIT) in helping patients maintain dietary consumption of allergenic foods over 12 months. The findings suggest that both treatment approaches may offer comparable long-term outcomes for individuals managing multiple severe food allergies.
The OUtMATCH Stage 3 study included 81 participants, 80 of whom qualified for dietary consumption plans involving one to three allergenic foods following treatment with either mOIT or omalizumab. “Dietary consumption” was defined as the daily ingestion of 300 mg of an allergenic food, tracked through participant diaries. Researchers then followed outcomes over a 12-month period.
At six months, success rates were similar between groups: 65% in the post-mOIT group and 63% in the post-omalizumab group. Investigators reported no significant differences between the groups at three-, six-, nine-, and twelve-month evaluations. After approximately one year on dietary consumption plans, more than 60% of participants in both groups were regularly ingesting their allergenic foods.
Lead author Sharon Chinthrajah, MD, FAAAAI, said the results are encouraging for families living with multiple food allergies, noting that both approaches appear to support sustained dietary inclusion with comparable overall outcomes.
Safety remained an important focus of the research. Among participants who continued dietary consumption plans for the full year, safety profiles were generally similar between the post-mOIT and post-omalizumab groups. Two serious adverse events occurred during the transition from mOIT to open dietary consumption. Additionally, one participant in the post-omalizumab group developed eosinophilic esophagitis during the dietary consumption phase. Overall, investigators reported no significant safety differences between the groups.
The findings, published in an online supplement to The Journal of Allergy and Clinical Immunology, provide clinicians and patients with additional evidence that both pharmacologic and immunotherapy-based strategies may support sustained dietary consumption goals in people with multiple food allergies.
